• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for NEXOBRID issued to MEDIWOUND, LTD

    12/30/22 4:38:06 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MDWD alert in real time by email
    Biologic License Application (BLA): 761192
    Company: MEDIWOUND, LTD
    • Email

    Products on BLA 761192

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    NEXOBRID ANACAULASE-BCDB 8.8% GEL;TOPICAL Prescription None No No

    Approval Date(s) and History, Letters, Labels, Reviews for BLA 761192

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    12/28/2022 ORIG-1 Approval N/A

    Label is not available on this site.

    Supplements
    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
    12/28/2022 SUPPL-1 Supplement Letter (PDF)

    Label is not available on this site.

    https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/761192Orig1s000ltr.pdf
    Get the next $MDWD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MDWD

    DatePrice TargetRatingAnalyst
    6/2/2025$34.00Outperform
    Oppenheimer
    5/2/2025$25.00Buy
    Alliance Global Partners
    2/28/2025$39.00Buy
    Craig Hallum
    7/16/2024$25.00 → $30.00Buy
    Maxim Group
    12/22/2022$11.00Buy
    Maxim Group
    7/18/2022$7.00Outperform
    Oppenheimer
    8/17/2021$10.00 → $9.00Buy
    Aegis Capital
    8/11/2021$7.00 → $6.50Buy
    HC Wainwright & Co.
    More analyst ratings

    $MDWD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer resumed coverage on MediWound with a new price target

      Oppenheimer resumed coverage of MediWound with a rating of Outperform and set a new price target of $34.00

      6/2/25 8:53:24 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Alliance Global Partners initiated coverage on MediWound with a new price target

      Alliance Global Partners initiated coverage of MediWound with a rating of Buy and set a new price target of $25.00

      5/2/25 8:15:09 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Craig Hallum initiated coverage on MediWound with a new price target

      Craig Hallum initiated coverage of MediWound with a rating of Buy and set a new price target of $39.00

      2/28/25 7:39:12 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MDWD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for NEXOBRID issued to MEDIWOUND, LTD

      Submission status for MEDIWOUND, LTD's drug NEXOBRID (SUPPL-10) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 08/15/2024. Application Category: BLA, Application Number: 761192, Application Classification:

      8/16/24 4:36:54 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • FDA Approval for NEXOBRID issued to MEDIWOUND, LTD

      Submission status for MEDIWOUND, LTD's drug NEXOBRID (ORIG-1) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761192, Application Classification:

      12/30/22 4:38:06 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • FDA Approval for NEXOBRID issued to MEDIWOUND, LTD

      Submission status for MEDIWOUND, LTD's drug NEXOBRID (SUPPL-1) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761192, Application Classification:

      12/29/22 1:11:07 PM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MDWD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update

      VALUE Phase III trial of EscharEx® in venous leg ulcers advancing as planned NexoBrid® manufacturing expansion on track; full operational capacity expected by year-end 2025 First quarter revenue of $4 million; full-year 2025 revenue guidance reaffirmed at $24 million Conference call today, May 21 at 8:30am Eastern Time YAVNE, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update. "We entered 2025 with strong execution across our clinical, commercial, and operational priorities, mainta

      5/21/25 7:00:00 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers

      YAVNE, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of a peer-reviewed post hoc analysis in Wounds. The analysis is based on data from the Company's Phase II ChronEx clinical trial in patients with venous leg ulcers (VLUs) evaluating the efficacy and safety of EscharEx® compared with collagenase ointment (SANTYL®), the only FDA-cleared enzymatic debridement agent commercially available for the treatment of dermal ulcers. The article, titled "Bromelain-Based Debridement Versus Collagenase Ointment Debridement of Venous Leg Ulcers: Post Hoc Analysis of

      5/13/25 7:30:00 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MediWound to Report First Quarter 2025 Financial Results

      YAVNE, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 21, 2025. Following the release, MediWound's management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates. Dial-in and call details are as follows: Conference Call & Webcast DetailsToll-Free:1-844-676-8833Israel:1-80-921-2373International:1-412-634-6869Webcast:Click HERE   To access the call, participan

      5/5/25 8:00:00 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MDWD
    SEC Filings

    See more
    • SEC Form 6-K filed by MediWound Ltd.

      6-K - MediWound Ltd. (0001593984) (Filer)

      5/21/25 7:07:42 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by MediWound Ltd.

      6-K - MediWound Ltd. (0001593984) (Filer)

      5/15/25 4:35:05 PM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by MediWound Ltd.

      6-K - MediWound Ltd. (0001593984) (Filer)

      4/7/25 4:04:11 PM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care